{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.8"},{"groupId":"OG001","value":"94.7"},{"groupId":"OG002","value":"89.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"77"}],"units":"Participants"}],"description":"Tumor response is defined as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) and is identified as per local practice. Clinical response rate is defined as the percentage of participants who achieve a response of CR or PR at any time pre-surgery. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by mammogram or magnetic resonance imaging (MRI) and clinical breast examination (CBE), CR is disappearance of all target lesions; PR is \\>=30% decrease in the sum of the longest diameter of target lesions.","groups":[{"description":"5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab and pertuzumab every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.","id":"OG000","title":"T+P Concomitant Anthracycline-based Chemotherapy"},{"description":"FEC every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.","id":"OG001","title":"T+P Sequential Anthracycline-based Chemotherapy"},{"description":"Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.","id":"OG002","title":"T+P Concomitant Non-Anthracycline Chemotherapy"}],"paramType":"NUMBER","populationDescription":"ITT population included all participants who were randomized to treatment.","reportingStatus":"POSTED","timeFrame":"During each 3-week cycle of 6 total cycles: up to 18 weeks","title":"Efficacy: Clinical Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}